• TREATMENT

    Network meta-analysis compares refractory-line options in KRAS-mutant metastatic CRC

    Analysis of 10 trials (3,959 patients) found fruquintinib, regorafenib, and TAS-102 all improved overall survival versus placebo; in KRAS-mutant tumors, fruquintinib and TAS-102 showed numerically favorable estimates, though indirect comparisons did not demonstrate superiority. (Front Oncol)